RPRX News Alert Repros Therapeutics Inc (RPRX) 8.88 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Repros Therapeutics Inc (RPRX) 8.88 $RPRX

5 Stocks Poised for Breakouts: RetailMeNot, Repros and More
at The Street - Fri Dec 19, 12:29PM CST
These are the stocks that often go on to make monster moves to the upside.
QEPM: 15.83 (-0.01), BDR: 2.36 (+0.06), CYBR: 41.60 (+0.59), SALE: 14.83 (+0.19), RPRX: 8.88 (+0.24)

Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), RTRX: 12.92 (+0.19), CYTR: 2.58 (+0.03), RPRX: 8.88 (+0.24), GALE: 1.49 (-0.02), AEGR: 21.59 (-0.27)

Earnings Look Back: Repros Therapeutics Is Down 4.7% Since Reporting Quarterly Results 2 Weeks Ago (RPRX)
Comtex SmarTrend(R) - Mon Nov 24, 9:51AM CST
When Repros Therapeutics (NASDAQ:RPRX) reported earnings two weeks ago on November 10th, 2014, analysts, on average, expected the company to report a loss of $0.39 on sales of $1.0 thousand. The company actually reported a loss of $0.32 per share on sales of $2.0 thousand, beating EPS estimates by $0.07 and matching revenue estimates. Since the company's report, shares of Repros Therapeutics have fallen from $9.22 to $8.79, representing a loss of 4.7% in the past 14 days.
RPRX: 8.88 (+0.24)

Earnings Look Back: Repros Therapeutics Is Up 1.3% Since Reporting Quarterly Results 1 Week Ago (RPRX)
Comtex SmarTrend(R) - Mon Nov 17, 4:05PM CST
7 days ago, on November 10th, 2014, Repros Therapeutics (NASDAQ:RPRX) reported its earnings. Analysts, on average, expected a loss of $0.39 per share on sales of $1.0 thousand. The company actually reported a loss of $0.32 per share on sales of $2.0 thousand, beating EPS estimates by $0.07 and matching revenue estimates. Since the company's report, shares of Repros Therapeutics have risen from $9.22 to $9.34, representing a gain of 1.3% in the past 7 days.
RPRX: 8.88 (+0.24)

Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CLUB: 5.90 (-0.07), HYGS: 13.33 (+0.06), KNDI: 12.90 (+0.99), MCEP: 6.07 (-0.12), HYG.TO: 15.50 (-0.16), RPRX: 8.88 (+0.24), SHLD: 32.56 (-0.37), PAA.TO: 10.51 (+0.27), PAAS: 9.05 (+0.25), REXX: 5.17 (-0.17), AKBA: 11.23 (-0.31), GCBC: 29.00 (-1.00), ASEI: 51.61 (+0.05), MTEX: 28.96 (unch), PLNR: 7.04 (-0.15)

Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 340.89 (+5.13), RPRX: 8.88 (+0.24), ABBV: 66.21 (+1.86), AMAG: 43.02 (+0.90)

Repros Therapeutics posts 3Q loss
Automated Insights - Mon Nov 10, 8:13AM CST
WOODLANDS, Texas (AP) _ Repros Therapeutics Inc. (RPRX) on Monday reported a loss of $7.4 million, or 32 cents per share, in its third quarter.
RPRX: 8.88 (+0.24)

Repros Therapeutics beats by $0.07
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:11AM CST

RPRX: 8.88 (+0.24)

Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 8:00AM CST
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2014.
RPRX: 8.88 (+0.24)

Sears Soars Nearly +40% As REIT News Boosts Confidence
at The Street - Fri Nov 07, 2:42PM CST
Repros Therapeutics Inc (NASDAQ:RPRX), Sears Holdings Corp (NASDAQ:SHLD) and Allied Nevada Gold Corp. (NYSEMKT:ANV) are among the top-gaining billionaire stock picks of the day. On the losing end ar...
ANV: 0.88 (+0.02), AMSC: 0.82 (+0.01), RPRX: 8.88 (+0.24), SHLD: 32.56 (-0.37), STAY: 19.60 (-0.31)

Midday Gainers/Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 11:52AM CST

ROKA: 4.60 (-0.09), NES: 4.96 (-0.44), FNGN: 37.85 (+0.79), FIVN: 4.56 (+0.11), MSON: 11.76 (+0.14), SLXP: 114.92 (-1.18), SUMR: 3.10 (+0.06), RPRX: 8.88 (+0.24), QTWO: 20.09 (-0.21), EV: 41.98 (-0.25), SHLD: 32.56 (-0.37), STAY: 19.60 (-0.31), PSIX: 53.57 (-0.12), BORN: 1.38 (+0.02), URRE: 1.93 (+0.01), ECOM: 21.95 (+0.19), ICPT: 151.49 (+5.85), SAEX: 4.60 (+0.05), VPCO: 1.30 (-0.01), SZYM: 2.70 (+0.04)

Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
at The Street - Fri Nov 07, 10:07AM CST
Shares of Repros Therapeutics (RPRX) soared in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its testosterone-boosting drug Androxal.
RPRX: 8.88 (+0.24)

Repros jumps after FDA meeting on Androxal NDA
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 9:20AM CST

RPRX: 8.88 (+0.24)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.48 (-0.15), ANET: 65.00 (+0.30), TKMR: 13.97 (+0.14), ORBC: 6.71 (+0.17), MDRX: 12.87 (-0.13), RMTI: 8.41 (-0.07), CTIC: 2.36 (+0.05), SHLD: 32.56 (-0.37), UBNT: 31.30 (+0.14), RIG: 18.77 (-0.37), KGC: 2.70 (+0.11), APT: 2.55 (-0.03), ANF: 28.06 (-0.17), MITK: 3.47 (-0.06), ZNGA: 2.71 (-0.01), CNET: 1.28 (-0.11), KING: 16.27 (+0.10), NETE: 1.20 (unch), SLXP: 114.92 (-1.18), RPRX: 8.88 (+0.24), NADL: 1.68 (-0.08), PGNX: 6.99 (-0.03), AVNR: 16.91 (+0.01), FSLR: 43.67 (-0.39), DVA: 76.06 (+0.07), NDLS: 25.88 (+0.20), ICPT: 151.49 (+5.85), AGIO: 109.67 (+2.45), PLNR: 7.04 (-0.15)

Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
GlobeNewswire - Thu Nov 06, 3:21PM CST
-- No New Clinical Studies Requested
RPRX: 8.88 (+0.24)

Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 97.84 (-0.29), PBH: 34.02 (+0.06), RPRX: 8.88 (+0.24), HSP: 62.60 (-0.07)

63.7% Return Seen to Date on SmarTrend Repros Therapeutics Call (RPRX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 63.72% as of today's recent price of $6.48.
RPRX: 8.88 (+0.24)

Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.61 (+0.06), PTX: 9.05 (+0.28), AKRX: 36.47 (+0.43), RPRX: 8.88 (+0.24), NKTR: 15.02 (+0.23)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 88

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 131

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 28

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 70

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 94

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading

Top 5 Most Recently Viewed Articles

Sigenergy Embraces AI in Smart Energy Solutions at Intersolar

Updated Category News Views 284

Sigenergy's Vision for Smart Energy Sigenergy recently showcased its dedication to innovative, AI-driven energy solutions during a major event at Intersolar 2025. This milestone reinforced the company's mission to develop a user-centered smart energy ecosystem. With over 500 attendees, the launch at Brainlab Tower highlighted Sigenergy's ambitious goal of redefining...

Continue Reading
Investor Insights on Charter Communications Earnings Report

Updated Category News Views 181

Anticipation Surrounding Charter Communications Earnings Charter Communications (NASDAQ: CHTR) is set to unveil its quarterly earnings in the near future. Investors are particularly eager to see if the company can surpass previous estimates and provide favorable outlooks for the upcoming quarters. Recent trends suggest that beat expectations could lead to positive stock...

Continue Reading
Intevac Welcomes Kevin Barber as New Chairman of the Board

Updated Category News Views 362

Intevac got hit with a leadership shakeup back in early 2024 when Kevin Barber took the reins as the new Board Chairman, stepping into some big shoes after David Dury. Traders were buzzing—who wouldn’t be? Dury had been at the helm since 2017, steering Intevac through several crucial transitions. But Barber's appointment felt like a fresh shot of adrenaline for...

Continue Reading
Insight Into the Growing Market for Display Cases Worldwide

Updated Category News Views 63

The Growing Popularity of Display Cases in Global Markets As retail continues to evolve, display cases have become essential for attracting customers. Their visual appeal significantly affects buying choices, leading businesses to invest in high-quality display options. Recent research shows that the demand for display cases is on the rise, with an expected annual growth...

Continue Reading
Medallion Secures $43 Million to Innovate Healthcare Credentialing

Updated Category News Views 347

Medallion Announces Major Funding to Revolutionize Credentialing Medallion has successfully raised $43 million to further develop its innovative AI-driven platform and to launch CredAlliance™, a groundbreaking credentialing clearinghouse aimed at streamlining provider onboarding and verification processes. Empowering Healthcare with Intelligent Automation With this new...

Continue Reading